Gene Symbol |
Aliases |
Editing Sites |
Enzyme |
Editing Type |
Molecular Consequence |
Editing Level |
Correlation |
Phenotype |
Disease |
CTSS
|
- |
41 |
ADAR1 |
A-to-I |
mRNA stability change |
Present |
Negative |
Reduce atherosclerosis and angiogenesis |
|
AZIN1
|
- |
2 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Present |
Positive |
Promote tumor cellular proliferation;Promote aggressive behaviors in tumor progression |
|
FLNB
|
- |
1 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Increased |
Positive |
Increase RNA editing level in disease; Induce malignant phenotypes during tumor progression |
|
COPA
|
- |
1 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Increased |
Positive |
Affect tumor pathogenesis |
|
IGFBP7
|
- |
3 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Positive |
Inhibit tumor cell apoptosis; Reduce RNA editing event promote tumor cell proliferation |
|
GRIA2
|
GLUR2 |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Negative |
Reduce RNA editing in disease |
|
GRIA3
|
GLUR3 |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Negative |
Promote recovery of spinal core injury |
|
GRIA4
|
GLUR4 |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Negative |
Promote recovery of spinal core injury |
|
GRIK1
|
GLUR5 |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Negative |
Reduce RNA editing in disease |
|
GRIK2
|
GLUR6 |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Decreased |
Negative |
Reduce RNA editing in disease |
|
HTR2C
|
- |
6 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Present |
Positive |
Induce disease |
|
RHOQ
|
- |
1 |
NA |
A-to-I |
Nonsynonymous substitution |
Increased |
Positive |
Promote recurrence |
|
PINK1
|
- |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Present |
Negative |
Repair mitophagy |
|
EDNRB
|
ETB |
1 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Present |
Positive |
Induce disease |
|
BLCAP
|
- |
12 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution; mRNA expression change |
Decreased |
Negative |
Reduce RNA editing in disease |
|
SLC1A2
|
EAAT2 |
1 |
ADAR1;ADAR2 |
A-to-I |
Alternative splicing |
Present |
Positive |
Affect disease processing |
|
PTPN6
|
- |
1 |
NA |
A-to-I |
Alternative splicing |
Present |
Positive |
Affect disease processing |
|
LDLR
|
- |
1 |
NA |
G-to-C |
Alternative splicing |
Present |
Positive |
Reduce hypercholesterolemia |
|
CDC14B
|
- |
13 |
ADAR2 |
A-to-I |
- |
Decreased |
Negative |
Reduce RNA editing in disease |
|
TPH2
|
- |
5 |
APOBEC |
A-to-I; G-to-A; C-to-U |
Alternative splicing |
Present |
Positive |
Affect disease processing |
|
HNRNPK
|
- |
1 |
APOBEC3B |
G-to-A |
Nonsynonymous substitution |
Present |
Positive |
Affect disease processing |
|
PODXL
|
- |
1 |
ADAR1;ADAR2 |
A-to-I |
Nonsynonymous substitution |
Absent |
Positive |
Reduce tumorigenic ability |
|
GLI1
|
- |
1 |
ADAR1 |
A-to-I |
Nonsynonymous substitution |
Present |
Positive |
Increase RNA editing level in disease |
|
NF1
|
- |
1 |
NA |
C-to-U |
Nonsynonymous substitution |
Increased |
Positive |
Increase RNA editing level in disease |
|
ARPIN
|
- |
2 |
ADAR1;ADAR2;ADAR3 |
A-to-I |
- |
Present |
Positive |
Promote the disease risk |
|
DHFR
|
- |
25 |
ADAR1 |
G-to-A |
mRNA expression change |
Increased |
Positive |
Promote tumor cell proliferation |
|
NEIL1
|
- |
1 |
ADAR1 |
A-to-I |
Nonsynonymous substitution |
Increased |
Positive |
Increase RNA editing level in disease |
|
WT1
|
- |
1 |
APOBEC3A |
G-to-A |
Nonsynonymous substitution |
Present |
Positive |
Induce mutation of wilms tumor and acute myeloid leukemia |
|
GABRA-3
|
- |
1 |
ADAR1;ADAR2 |
G-to-A |
Nonsynonymous substitution |
Present |
Positive |
Affect the variability GABAA receptors in sensitivity to drugs |
|
SLC22A3
|
- |
1 |
ADAR2 |
A-to-I |
Nonsynonymous substitution |
Present |
Positive |
Promote the tumor progression and malignant development |
|
FLNA
|
- |
1 |
ADAR1;ADAR2 |
NA |
Nonsynonymous substitution |
Decreased |
Negative |
Exacerbation the psoriasis |
|
CDK13
|
- |
2 |
ADAR1 |
A-to-I |
Nonsynonymous substitution |
Increased |
Positive |
Affect HCC tumor tissues and associated with poor prognosis |
|
HNRPLL
|
SRRF; HNRPLL |
3 |
ADAR1;ADAR2 |
NA |
Alternative splicing |
Present |
Positive |
RNA editing of HNRPLL generates a novel splicing variant linked to cell proliferation |
|
COG3
|
SEC34 |
1 |
ADAR2 |
NA |
Recoding |
Present |
Negative |
Over-editing (>40%) at the COG3 I/V site with a worse prognosis in GBM patients |
|
PDE8A
|
HsT19550 |
5 |
ADAR1 |
NA |
mRNA expression change |
Increased |
Positive |
RNA editing play an important role in the initiation and propagation of SLE pathogenesis;RNA-editing providing a marker for discriminating between suicides and control groups |
|
XIAP
|
API3; ILP1; MIHA; XLP2; BIRC4; IAP-3; hIAP3; hIAP-3 |
31 |
ADAR1 |
NA |
protein products expression change |
Present |
Positive |
Edited XIAP suppressed the XIAP-dependent apoptotic response |
|
MDM2
|
HDMX; hdm2; ACTFS |
5 |
ADAR1 |
NA |
protein products expression change |
Present |
Positive |
Edited MDM2 suppressed the MDM2-dependent apoptotic response |
|
DFFA
|
DFF1; ICAD; DFF-45 |
1 |
ADAR1 |
A-to-I |
miRNA binding sites gain |
Present |
NA |
Dfferential RNA editing of DFFA in two cell lines(MCF-7 |
|
ABCA5
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ADAM22
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ADGRB3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ANAPC5
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ANK3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ARHGEF11
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ARNT2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ASIC2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ATM
|
|
21 |
ADAR1 |
A-to-I |
mRNA expression change |
Increased |
Positive |
Increasing the editing in the 3′UTRs of ATM transcripts in tumors
|
|
ATP2B2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ATRNL1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
C10orf113
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
C11orf58
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
C1orf95
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CABP1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CACNB2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CADM2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CADPS
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CCDC15
|
|
4 |
ADAR1 |
A-to-I |
Alternative splicing change |
Presence |
Positive |
Exon 9-included CCDC15 and exon 3-included RELL2 isoforms are oncogenic and tumor suppressive
|
|
CCDC84
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CDS2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CERS4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CLASP1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CLASP2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CNTNAP2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CNTNAP4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
COA4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CSMD1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
CTNNA2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DANT2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DGCR5
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DGKZ
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DLG2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DLGAP1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DNAJC6
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
DPP10
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
EPS15
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FAK
|
|
1 |
ADAR1 |
A-to-I |
mRNA stability change |
Presence |
Negative |
FAK blocked ADAR-induced invasiveness of LUAD cells
|
|
FAM155A
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FGF12
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FGF14
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FMNL2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FRMD4A
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FTX
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
FUT9
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GFOD2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GINS4
|
|
44 |
ADAR1 |
A-to-I |
mRNA expression change |
Increased |
Positive |
Increasing the editing in the 3′UTRs of GINS4 transcripts in tumors
|
|
GNL3L
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GOLGA3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GPCPD1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GPM6A
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
GRM7
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
HLTF
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
HP1BP3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
IBA57
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
IFNGR1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ILDR2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
JMJD1C
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KATNBL1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KCNIP4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KCNQ3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KCTD16
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KHDRBS3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KIAA1211L
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
KLHL11
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LAMTOR3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LIMCH1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LINC-PINT
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LOC101928961
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LOC171391
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
LRRC4C
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MAGI2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MAP4K3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MAPK10
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MATR3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MED13
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
METTL6
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MIAT
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MIR22HG
|
|
1 |
NA |
NA |
NA |
NA |
Negative |
It is a potential as a biomarker for several cancers
|
|
MKLN1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MON2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MSRA
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MTPAP
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MTR
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
MTUS1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NCKAP1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NOVA1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NRXN1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NRXN3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NSMAF
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NUP43
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
NXPE3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
OXR1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PAPD4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PCDH9
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PGK1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PLCB1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
POLH
|
|
156 |
ADAR1 |
A-to-I |
mRNA expression change |
Increased |
Positive |
Increasing the editing in the 3′UTRs of POLH transcripts in tumors
|
|
POLR2F
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PPP2R2B
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PREPL
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
PTPRD
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
R3HDM1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RALYL
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RBM5
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RELL2
|
|
1 |
ADAR2 |
A-to-I |
Alternative splicing change |
Presence |
Positive |
Exon 9-included CCDC15 and exon 3-included RELL2 isoforms are oncogenic and tumor suppressive
|
|
RGS7
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RIMS2
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RTN3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
RTN4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SERPINI1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SFXN5
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SHC3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SHISA9
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SHTN1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SLC25A27
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
SRSF5
|
|
1 |
NA |
NA |
NA |
NA |
Negative |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
STRBP
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
SRSF5 is involved in cancer development
|
|
SYT1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
TMEM161B-AS1
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
TRIM65
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
TTLL7
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
UBE2D3
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
VEZT
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
VPS13C
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
WDR33
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
XKR4
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
XKR6
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZNF264
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZNF37BP
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZNF529
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZNF680
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZNF708
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|
ZYG11B
|
|
1 |
ADAR1 |
A-to-I |
mRNA expression change |
Presence |
Positive |
RNA editing could contribute towards aberrant synaptic formation in ASD
|
|